Form D · Biotechnology
EIGER BIOPHARMACEUTICALS INC
Palo Alto, CA · CIK 0001454815
Offering snapshot reported Nov 20, 2015 · SEC filing
- Reported sold
- $6M Offering amount: $6M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 12, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 20, 2015 | Initial | $6,000,000 | No comparison | 4 | SEC filing |
| Mar 24, 2015 | Amendment | $14,462,851 | $5,722,221vs Feb 17, 2015 | 8 | SEC filing |
| Feb 17, 2015 | Amendment | $8,740,630 | $1,499,999vs Nov 20, 2014 | 8 | SEC filing |
| Nov 20, 2014 | Amendment | $7,240,631 | $327,508vs Sep 5, 2014 | 8 | SEC filing |
| Sep 5, 2014 | Amendment | $6,913,123 | $1,100,000vs Apr 11, 2014 | 8 | SEC filing |
| Apr 11, 2014 | Amendment | $5,813,123 | $500,001vs May 14, 2013 | 8 | SEC filing |
| May 14, 2013 | Amendment | $5,313,122 | $755,554vs Aug 29, 2012 | 8 | SEC filing |
| Aug 29, 2012 | Amendment | $4,557,568 | $1,007,568vs Apr 27, 2011 | 8 | SEC filing |
| Apr 27, 2011 | Initial | $3,550,000 | No comparison | 4 | SEC filing |
| Sep 20, 2010 | Amendment | $8,300,000 | No comparison | 9 | SEC filing |
| Jan 21, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-251688
Source: Form D, filed Nov 20, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Cory | Director, Executive |
| Thomas Dietz | Director |
| Ed Engleman | Director |
| Jeffrey Glenn | Director |
| Nina Kjellson | Director |
| Glen Sato | Executive |
| Paul Truex | Director |
| Keith Vendola | Executive |
| Wenjin Yang | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
350 Cambridge Avenue Suite 350
Palo Alto, CA, 94306
Palo Alto, CA, 94306